DALLAS, Aug. 4, 2015 /PRNewswire-iReach/ -- The report "Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline Review, H1 2015" provides comprehensive information on the therapeutic development for Attention Deficit Hyperactivity Disorder (ADHD), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Attention Deficit Hyperactivity Disorder (ADHD) and special features on late-stage and discontinued projects.

Photo - http://photos.prnewswire.com/prnh/20150804/254448

Complete report on 2015 Pipeline Review of Attention Deficit Hyperactivity Disorder (ADHD) with 58 market data tables and 16 figures, spread across 182 pages is available at http://www.rnrmarketresearch.com/attention-deficit-hyperactivity-disorder-adhd-pipeline-review-h1-2015-market-report.html .

Companies discuss in this report includes Alcobra Ltd, Amarantus Bioscience Holdings, Inc., Arbor Pharmaceuticals, LLC., Cerecor Inc., Collegium Pharmaceutical, Inc., Curemark, LLC, DURECT Corporation, Eli Lilly and Company, H. Lundbeck A/S, Hisamitsu Pharmaceutical Co., Inc., Integrative Research Laboratories Sweden AB, Intra-Cellular Therapies, Inc., KemPharm, Inc., Merck & Co., Inc., Mnemosyne Pharmaceuticals, Inc., Neos Therapeutics, Inc., NeuroDerm Ltd., Otsuka Holdings Co., Ltd., P2D Bioscience, Polleo Pharma Limited, Reviva Pharmaceuticals Inc., Samyang Biopharmaceuticals Corporation, Shire Plc, Signature Therapeutics, Inc, Sunovion Pharmaceuticals Inc., Supernus Pharmaceuticals, Inc., Taisho Pharmaceutical Co., Ltd., Takeda Pharmaceutical Company Limited, Tris Pharma, Inc., Vernalis Plc.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data in relation to the equipment type.

Drugs profile discussed in this report include (nicotine + opipramol hydrochloride), amfetamine XR, AR-08, BLI-1008, BNC-375, brexpiprazole, centanafadine IR, centanafadine SR, CM-4612, CTX-1301, CTX-1302, dasotraline, dextroamphetamine, dextroamphetamine MR, Drug for Attention Deficit Hyperactivity Disorder, edivoxetine, eltoprazine, etiguanfacine, guanfacine hydrochloride ER, HTL-1071, IRL-752, ITI-214, KP-415 CR, lisdexamfetamine dimesylate, Metadoxine ER, methylphenidate, methylphenidate hydrochloride, methylphenidate hydrochloride, methylphenidate hydrochloride SR, methylphenidate hydrochloride XR, MGS-0028, molindone hydrochloride ER, PBF-509, PD-2005, PD-2007, PFR-08001, PFR-8026, RP-5063, SHP-465, Small Molecule for ADHD, Small Molecules for Attention Deficit Hyperactivity Disorder, Small Molecules to Agonize NMDA2D for ADHD, Small Molecules to Antagonize H3 Receptor for ADHD And Alzheimer's Disease, Small Molecules to Inhibit COMT for Cognitive Disorders, Small Molecules to Inhibit Dopamine Transporter for CNS and Metabolic Disorders, Small Molecules to Inhibit Sodium Hydrogen Exchanger for ADHD, Small Molecules to Modulate Choline Transporter for ADHD, TAK-137, TRI-102, V-81444, viloxazine hydrochloride, vortioxetine hydrobromide.

Order a purchase copy @ http://www.rnrmarketresearch.com/contacts/purchase?rname=397265. (This is a premium report priced at US$2000 for a single user License.)

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

Table of Contents

Partial List of Tables
Number of Products under Development for Attention Deficit Hyperactivity Disorder (ADHD), H1 2015 13
Number of Products under Development for Attention Deficit Hyperactivity Disorder (ADHD) - Comparative Analysis, H1 2015 14
Number of Products under Development by Companies, H1 2015 16
Number of Products under Development by Companies, H1 2015 (Contd..1) 17
Number of Products under Development by Companies, H1 2015 (Contd..2) 18
Number of Products under Investigation by Universities/Institutes, H1 2015 19
Comparative Analysis by Late Stage Development, H1 2015 20
Comparative Analysis by Clinical Stage Development, H1 2015 21
Comparative Analysis by Early Stage Development, H1 2015 22
Comparative Analysis by Unknown Stage Development, H1 2015 23
Products under Development by Companies, H1 2015 24
Products under Development by Companies, H1 2015 (Contd..1) 25
Products under Development by Companies, H1 2015 (Contd..2) 26
Products under Development by Companies, H1 2015 (Contd..3) 27
Products under Investigation by Universities/Institutes, H1 2015 28
Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by Alcobra Ltd, H1 2015 29

List of Figures
Number of Products under Development for Attention Deficit Hyperactivity Disorder (ADHD), H1 2015 13
Number of Products under Development for Attention Deficit Hyperactivity Disorder (ADHD) - Comparative Analysis, H1 2015 14
Number of Products under Development by Companies, H1 2015 15
Number of Products under Investigation by Universities/Institutes, H1 2015 19
Comparative Analysis by Late Stage Development, H1 2015 20
Comparative Analysis by Clinical Stage Development, H1 2015 21
Comparative Analysis by Early Stage Products, H1 2015 22
Assessment by Monotherapy Products, H1 2015 59
Number of Products by Top 10 Targets, H1 2015 61
Number of Products by Stage and Top 10 Targets, H1 2015 61
Number of Products by Top 10 Mechanism of Actions, H1 2015 63
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015 63
Number of Products by Top 10 Routes of Administration, H1 2015 65
Number of Products by Stage and Top 10 Routes of Administration, H1 2015 65
Number of Products by Top 10 Molecule Types, H1 2015 67
Number of Products by Stage and Top 10 Molecule Types, H1 2015 67

Explore more reports on Neurology therapeutics at http://www.rnrmarketresearch.com/reports/life-sciences/pharmaceuticals/therapeutics/neurology-therapeutics .

About Us:

RnRMarketResearch.com is a database of selected syndicated market reports for global and China industries including but not limited to life sciences, information technology & telecommunications, consumer goods, food and beverages, energy and power, automotive and transportation, manufacturing and construction, materials and chemicals, public sector as well as business and financial services.

Media Contact: Ritesh Tiwari, RnR Market Research, +1888391544, sales@rnrmarketresearch.com

News distributed by PR Newswire iReach: https://ireach.prnewswire.com

SOURCE RnR Market Research